title: Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation.
abstract: Anticoagulation therapy is essential to reduce the risk of stroke in patients with atrial fibrillation. Traditionally, clinical trials have focused only on determining the efficacy and safety of anticoagulation but not on quality of life. In the last few years there has been a growing interest in determining the quality of life of patients treated with oral anticoagulation. In fact, specific tools that can evaluate quality of life related to atrial fibrillation and anticoagulation have been developed. Vitamin K antagonists have been shown to be effective in the prevention of thromboembolic complications. However, the use of vitamin K antagonists implies changes in behavior and lifestyle modifications that may have a negative impact on the quality of life. It has been suggested that self-monitoring of international normalized ratio could improve this impact. On the other hand, as new oral anticoagulants overcome these limitations, they may improve quality of life related with anticoagulant therapy. Unfortunately, although encouraging, the clinical experience with them is still quite limited.
authors: Servicio de Cardiología, Hospital 12 de Octubre, Madrid, Spain.
authors: Fernando Arribas
authors: FA
authors: Ynsaurriaga
authors: Rafael Peinado
authors: RP
authors: Peinado
authors: José Miguel
authors: JM
authors: Ormaetxe Merodio
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D014943:Global Health; D006801:Humans; D015994:Incidence; D011379:Prognosis; D011788:Quality of Life; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants
keywords: anticoagulation; apixaban; atrial fibrillation; dabigatran; quality of life; rivaroxaban; treatment; warfarin